Answers are grounded in this paper and cite their sources.
Increasing the dose of MTX and adding procarbazine and vincristine improved disease control and overall survival in patients with newly diagnosed PCNSL. Younger patients in particular fared extremely well with this treatment regimen. In older patients, deferring whole-brain RT did not compromise overall survival but did reduce treatment-related toxicity.
No takes yet. Share an insight, caveat, or question.
Abrey et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: